Indications -- diabetes Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- diabetes

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	5/5/2004 2:20:59 PM
From: tuck	Read Replies (1) of 278

[Inhaled insulin -- antibodies a long term problem after all? ARDM, NKTR, AEGN; GNBT, EMIS] Given ARDM/Novo's recent setback with respect to post-prandial blood glucose profiles: Message 20078832 and the possible involvement of circulating antibodies previously thought to be not neutralizing: Message 20079732 I have to wonder if inhaled insulin isn't really dead now. Which would make NKTR/PFE's Exubera a failure/short candidate (as they haven't released their data on this stuff -- or don't have it, and I'll bet the FDA AC will want it). And which would make Generex' (GNBT) buccal delivery system seem relatively promising, as it doesn't involve pulmonary delivery. Perhaps EMIS, too? Further background, containing references: eric.vcu.edu medscape.com medscape.com Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next